Northfield Laboratories Inc. Announces Third Quarter 2006 Financial Results Webcast
April 04 2006 - 7:00AM
Business Wire
Northfield Laboratories Inc. (Nasdaq: NFLD), announced today that
the Company will host its second quarter 2006 earnings conference
call with the financial community on Tuesday, April 11, 2006, at
11:00 a.m. Eastern Time (10 a.m. Central Time). This call is being
webcast by Thomson/CCBN and can be accessed at Northfield's Web
site at http://www.northfieldlabs.com. A replay will be available
in the same location for two weeks following the call. The webcast
is also being distributed through the Thomson StreetEvents Network
to both institutional and individual investors. Individual
investors can listen to the call at http://www.fulldisclosure.com,
Thomson/CCBN's individual investor portal, powered by StreetEvents.
Institutional investors can access the call via Thomson's
password-protected event management site, StreetEvents
(http://www.streetevents.com ). Investors may also dial
866.800.8652 and enter the passcode 28793528. A replay of the call
will be available by dialing 888.286.8010 and entering the passcode
83238803. About Northfield Laboratories Northfield Laboratories
Inc. is a leader in developing an oxygen-carrying resuscitative
fluid, PolyHeme(R), for the treatment of urgent, large volume blood
loss in trauma and resultant surgical settings. PolyHeme(R) is a
solution of chemically modified human hemoglobin that requires no
cross matching and is therefore compatible with all blood types. It
has a shelf life in excess of 12 months. Enrollment is currently
underway in a pivotal Phase III study of PolyHeme(R) beginning in
the pre-hospital setting. For further information about Northfield
Laboratories, visit www.northfieldlabs.com. This press release may
contain forward-looking statements concerning, among other things,
Northfield's future business plans and strategies and clinical and
regulatory developments affecting our PolyHeme blood substitute
product. These forward-looking statements are identified by the use
of such terms as "intends," "expects," "plans," "estimates,"
"anticipates," "should," "believes" and similar terms. These
forward-looking statements involve inherent risks and
uncertainties. Our actual results may therefore differ materially
from those predicted by the forward-looking statements because of
various factors and possible events, including our ability to
obtain FDA approval to market PolyHeme commercially, the
availability of capital to finance our clinical trials and ongoing
business operations, our ability to obtain adequate supplies of raw
materials and to manufacture PolyHeme in commercial quantities, our
ability to market PolyHeme successfully, the possibility that
competitors will develop products that will render PolyHeme
obsolete or non-competitive, our ability to protect our
intellectual property rights, the possibility that we may be
subject to product liability claims and other legal actions, our
dependency on a limited number of key personnel, the uncertainty of
Fourth, Final party reimbursement for our product and other risks
and uncertainties described from time to time in our periodic
reports filed with the Securities and Exchange Commission,
including our most recently filed quarterly report on Form 10-Q and
annual report on Form 10-K. These forward-looking statements speak
only as of the date of this press release. We do not undertake any
obligation to update or publicly release any revisions to
forward-looking statements to reflect events, circumstances or
changes in expectations after the time such statement is made. All
subsequent written and oral forward-looking statements attributable
to Northfield or any person acting on our behalf are qualified by
this cautionary statement.
Northfield labs (NASDAQ:NFLD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Northfield labs (NASDAQ:NFLD)
Historical Stock Chart
From Jul 2023 to Jul 2024